MSCI Launches First Suite of Digital Assets Indexes
MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, today announced the launch of digital-asset indexes, offering a way to help investors evaluate sources of risk and return opportunities across the global digital-assets ecosystem.
These digital-asset indexes are the first of their kind from MSCI and seek to track the performance of the largest digital assets by market capitalization; digital assets that utilize ex-proof-of-work blockchain consensus mechanisms; and digital assets associated with technology platforms supporting smart-contracts.
The new indexes will leverage insights based on collaboration with experts such as Menai Financial Group (“Menai”), a leading provider of institutional-grade digital-asset investment products and trading services. The indexes will consist of a blend of single-digital-asset indexes designed and published by Compass Financial Technologies (“Compass”), a leading service provider on digital assets which specializes in the design, calculation and publication of market benchmarks, financial indexes, and quantitative investment strategies.
Menai’s expertise in digital assets continues to inform MSCI’s development of its digital assets solutions, which help investors to navigate the investment universe for digital assets, evaluate risks and challenges, and assess emerging opportunities and developments as the rapidly growing industry drives technological change. Compass, an independent Swiss-based company focused on the design, calculation and administration of market benchmarks and quantitative investment strategies, created the single-digital-asset indexes that are the foundational building blocks for MSCI’s new blended indexes.
Stephane Mattatia, Head of Thematic Indexes at MSCI, said: “The digital assets ecosystem is evolving rapidly along with investor demand for tools and solutions to help navigate this new asset class. Global investors are looking for greater transparency and insight into these markets and how best to participate in them in a manner that meets their high standards for professionalism, scale, risk management, and security. The launch of these indexes embodies MSCI’s commitment to bringing clarity to diverse asset classes and to create solutions that capture long-term, disruptive investment trends. MSCI takes a systematic and process-oriented approach in providing information to help investors gain transparency and make better investment decisions.”
About the indexes:
|
Index |
Summary |
|
MSCI Global Digital Assets Indexes |
Two separate indexes that aim to represent the performance of the top 30 or top 20 digital assets, respectively, as measured by their full market capitalization (excluding stablecoins). |
|
MSCI Global Digital Assets ex Proof-of-work Index |
Aims to represent the performance of digital assets, selected by market capitalization, that do not rely on a proof-of-work consensus mechanism. A consensus mechanism, also referred to as consensus protocol, allows a computer network to coordinate a distributed ledger. It allows a general agreement to be achieved by all participant nodes. A proof-of-work consensus mechanism requires substantial, energy-consuming computational work for the creation of new blocks containing transactions in the distributed ledger. |
|
MSCI Global Digital Assets Smart Contract Index |
Aims to represent the performance of digital assets, selected by market capitalization, that are associated with technology platforms supporting “Smart Contracts” features. A Smart Contract is a digital program that runs on a blockchain. It is a collection of programs and data that resides at a specific address on the underlying blockchain. Digital assets that support Smart Contracts functionality are capable of being used by a wide range of decentralized applications across industries. |
The indexes will use datonomyTM – a new classification system for the digital assets market. Delivered as a new data service, datonomy classifies coins and tokens based on how they are used. Designed to provide a consistent, standardized way to help market participants view and analyze the digital assets ecosystem, datonomy will help create an increased level of transparency into how the market is moving and can be licensed for a variety of use cases, such as the review and assessment of portfolio performance and reporting.
MSCI is the owner and sole administrator of this new classification system and may receive input on potential changes from the datonomy Advisory Board (“Advisory Board”), as well as other market participants. The Advisory Board members will be comprised of Goldman Sachs, MSCI, Coin Metrics as well as third parties that can provide expertise on maintaining datonomy. Inaugural third-party members will be announced at a later date.
About MSCI Inc.
MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 50 years of expertise in research, data, and technology, we power better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios. We create industry-leading research-enhanced solutions that clients use to gain insight into and improve transparency across the investment process.
The digital asset taxonomy named datonomy™ is owned and administered by MSCI and was developed by Goldman Sachs, MSCI, and Coin Metrics. None of Goldman Sachs, MSCI, Coin Metrics or any other party involved in or related to compiling, computing or creating datonomy makes any express or implied warranties or representations with respect to datonomy (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to datonomy. Datonomy does not constitute investment advice, is not a solicitation or recommendation to buy or sell, or an endorsement of, any assets, does not assess, classify or make any statement regarding the regulatory status or standing of an asset, and no assurance is provided of the results of any investment or investment strategy using datonomy. Without limiting any of the foregoing, in no event shall Goldman Sachs, MSCI, or Coin Metrics, or any of their affiliates or any third party involved in or related to compiling, computing, creating or licensing the data have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution, dissemination or use of datonomy is permitted without the express written consent of one of Goldman Sachs, MSCI, or Coin Metrics, including using datonomy for investment purposes.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or performance and involve risks that may cause actual results or performance differ materially and you should not place undue reliance on them. Risks that could affect results or performance are in MSCI’s Annual Report on Form 10-K for the most recent fiscal year ended on December 31 that is filed with the SEC. MSCI does not undertake to update any forward-looking statements. No information herein constitutes investment advice or should be relied on as such. MSCI grants no right or license to use its products or services without an appropriate license. MSCI MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR OTHERWISE WITH RESPECT TO THE INFORMATION HEREIN AND DISCLAIMS ALL LIABILITY TO THE MAXIMUM EXTENT PERMITTED BY LAW.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005909/en/
Contact information
Media Inquiries
PR@msci.com
Sam Wang
+1 212 804 5244
Melanie Blanco
+1 212 981 1049
Tina Tan
+852 2844 9320
MSCI Global Client Services
EMEA Client Service
+ 44 20 7618.2222
Americas Client Service
+1 888 588 4567 (toll free)
Asia Pacific Client Service
+ 852 2844 9333
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom